Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid

Runtao He, a,b,*,1 Anton Adonov, a,b,1 Maya Traykova-Adonova, a Jingxin Cao, a,b Todd Cutts, a Elsie Grudesky, a Yvon Deschambaul, a Jody Berry, a,b Michael Drebot, a,b and Xuguang Li c

a National Microbiology Laboratory, Health Canada, 1015 Arlington St., Winnipeg, MB, Canada R3E 3R2
b Department of Medical Microbiology, School of Medicine, University of Manitoba, Winnipeg, MB, Canada R3T 2N2
c Centre for Biologics Research, Biologics and Genetic Therapies Directorate, Health Canada, Tunney’s Pasture, Ottawa, ON, Canada K1A 0K9

Received 27 May 2004
Available online 2 July 2004

Abstract

The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse reactions have been reported to some veterinary coronavirus vaccines, anti-viral compounds must be relentlessly pursued. In this study, we analyzed the effect of aurintricarboxylic acid (ATA) on SARS-CoV replication in cell culture, and found that ATA could drastically inhibit SARS-CoV replication, with viral production being 1000-fold less than that in the untreated control. Importantly, when compared with IFNs α and β, viral production was inhibited by more than 1000-fold as compared with the untreated control. In addition, when compared with IFNs α and β, ATA was approximately 10 times more potent than IFN α and 100 times more than interferon β at their highest concentrations reported in the literature previously. Our data indicated that ATA should be considered as a candidate anti-SARS compound for future clinical evaluation.

© 2004 Elsevier Inc. All rights reserved.

Keywords: SARS; Coronavirus, SARS-CoV; Aurintricarboxylic acid; Inhibition

A new coronavirus that caused severe acute respiratory syndrome (SARS) was identified in early 2003, and subsequently named as SARS coronavirus (SARS-CoV). The virus has a high tendency to spread among humans, and the mortality can be as high as 10–15% [1,2]. The complete understanding of pathogenesis of SARS remains tentative, a recent histological study using SARS-CoV-infected patient lung samples found that diffuse alveolar damage may play important roles in the progression of the disease [3]. Even though there was a significant morbidity drop this year, the likelihood of evolution of SARS-CoV in human and animals may result in a re-emergence of the deadly virus.

Coronaviruses are enveloped viruses with single-stranded positive-sense RNA genomes approximately 30 kb [4]. Most viruses in coronavirus family cause diseases in animal, while a few of them; such as HCoV-229E, HCoV OC43, HCoV-NL-63, and SARS-CoV are human pathogens [5–7]. Among all human coronaviruses, SARS-CoV is the only one that causes severe clinical consequences. Sequence comparisons of SARS-CoV genome sequences from different patient isolates revealed high homology; yet, the sequence difference between SARS-CoV and other coronaviruses is significant. There are about 15 predicted open reading frames, among them six can be linked to other known coronavirus genes. These genes are 1a–1b, spike (S), envelope
were performed 24 h post-infection using procedures as described [16]. Serial dilutions composed of 0.8, 0.4, and 0.2 mg/ml. Plaque assays, ribavarin was shown to have little effect against SARS-CoV replication. As shown in Fig. 1, in comparison with the untreated cells, more than 1000-fold inhibition of the virus replication was observed when the culture was treated with ATA at a concentration of 0.8 mg/ml, while at least 100-fold inhibition at 0.4 mg/ml. Such inhibitory effect on viral replication could still be observed at 0.2 mg/ml, with viral replication level being 10 times lower than that of the control.

We also performed the inhibition analysis with interferons α and β both at the concentration of 5000 IU/ml [10,12].

Western blotting. Protein samples from Vero cell extracts were fractionated on 4–12% SDS-PAGE (Invitrogen, Carlsbad, CA) and transferred to PVDF membrane using semi-dry protein transfer apparatus (Bio-Rad, Hercules CA). The membrane was blocked for 1 h with 5% skim milk in TBS buffer (20 mM Tris base, 137 mM NaCl, pH 7.6) containing 0.2% Tween 20. The membrane was then probed with a mouse monoclonal antibody against SARS-CoV spike protein (unpublished data). Rabbit anti-mouse HRP-conjugated antibody (Amersham Biosciences, Piscataway, NJ) was subsequently added for an additional incubation of 1 h at 37°C. The results were finally revealed by using Pierce Biotechnology SuperSignal West Femto Maximum Sensitivity Substrate (Rockford, IL).

Materials and methods

Cell culture and viral plaque assay. The African green monkey kidney cell line Vero cells were cultured in Dulbecco’s modified Eagle’s medium, supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA), 1% penicillin/streptomycin, and 10 mM Heps (pH 7.2). Vero cells have been shown to be susceptible to SARS-CoV infection [4]. All cell cultures were maintained in a humidified 5% CO2 incubator at 37°C. In all the experiments, the multiplicity of infection (MOI) was 0.01. Aurintricarboxylic acid (ATA) has been shown to interact with ribosomal proteins in vitro and inhibit the virus [13]. It has also been shown that ATA could interact with ribosomal proteins in vitro and inhibit the protein synthesis [14,15]. In this study, we studied the antiviral effects of ATA against SARS-CoV replication in Vero cells and found that ATA drastically inhibited the virus replication by as much as 1000-fold compared to the untreated controls, while little toxicity has been observed to be associated with ATA treatment. Antiviral selectivity of ATA was demonstrated by its failure to inhibit adenovirus replication. Importantly, we found that ATA is a much potent anti-SARS-CoV compound than IFNs α and β.

Inhibition of SARS-CoV replication by ATA

We have tested the anti-SARS-CoV effect of aurintricarboxylic acid (ATA) over a wide range of concentrations, i.e., 0.8, 0.4, and 0.2 mg/ml prepared in minimum essential medium (MEM) with 10 mM Heps (pH 7.2) and 10% of fetal calf serum. Plaque assays were used to determine the effect of ATA on SARS-CoV replication. Vero cells were infected with SARS-CoV in a 24-well plate; serial dilutions of ATA were added to the infected cells after the initial virus adsorption step. Twenty-four hours post-infection, we collected the supernatants from the aforementioned cultures for plaque assays to determine the inhibitory effect of ATA on SARS-CoV replication. As shown in Fig. 1, in comparison with the untreated cells, more than 1000-fold inhibition of the virus replication was observed when the culture was treated with ATA at a concentration of 0.8 mg/ml, while at least 100-fold inhibition at 0.4 mg/ml. Such inhibitory effect on viral replication could still be observed at 0.2 mg/ml, with viral replication level being 10 times lower than that of the control.
We also compared the inhibitory effect of ATA on SARS-CoV replication with that of a previously reported one on IFNs α and β. To this end, dilutions of ATA and IFNs at the highest concentrations to be effective were used to treat the cultures [10,12], followed by determination of virus loads. The virus loads at 24 h post-infection were quantified by real-time RT-PCR analysis using specific primers and probes against SARS-CoV nucleocapsid protein. As shown in Fig. 2A, ATA at 0.8 mg/ml inhibited the virus RNA replication by more than 1000-fold versus 100-fold inhibition by interferon α at 5000 IU/ml and 10-fold by interferon β at 5000 IU/ml (Fig. 2A). This result suggested that ATA was about 10 times more potent than interferon α and 100 times more potent than interferon β for anti-SARS-CoV activities.

To further analyze whether there is a prophylactic effect of ATA, we pre-treated the cells with series of concentrations of ATA, interferons α and β for 12 h before the adsorption of SARS-CoV to Vero cells and then added the above inhibitors after adsorption. As shown in Fig. 2B, the inhibition effect of ATA and interferons α and β was about the same as samples without the pre-treatment, implicating that the inhibition effect may take place after the virus enter the cells.

**Western blot analysis**

To further confirm the inhibitory effect, we performed Western blot analysis using a monoclonal antibody against SARS-CoV spike (S) protein. As shown in Fig. 3A, the level of the S protein was significantly lower in the ATA treated group than in the untreated group.

At the concentration of 0.8 mg/L, ATA virtually blocked viral protein synthesis, confirming that ATA can significantly inhibit the viral protein synthesis.

To characterize the specificity of anti-viral activity of ATA, we also tested the compound for its ability to block the protein expression by adenovirus replication. The replication deficient adenovirus type 5 expressing EGFP was used to infect HEK-293 cells. The same concentrations of ATA used in the above-mentioned SARS-CoV inhibition experiment were added to the adenovirus-infected cells. A Western blot analysis was subsequently performed to determine the expression level of EGFP. No significant inhibition was observed in any ATA-treated samples compared with non-ATA-treated cells (Fig. 3B), suggesting that the inhibition of SARS-CoV replication by ATA was clearly selective.
While EC$_{50}$ means the concentration of inhibitors that inhibit 50% of SARS-CoV replication (EC$_{50}$), and SI of ATA is 187 versus 30 of IFN-α and 20 of IFN β; indicating ATA has a great potential to be a potent antiviral compound with low toxicity (Table 1).

Because of its low toxicity in cell culture and animals [17,18], ATA has been evaluated for its anti-viral activities such as immunodeficiency virus type I [17,19]. However, the mechanism involved in its ability of inhibiting virus replication in those studies remains largely unknown, as is also the case in our current studies on SARS-CoV. The potency of ATA against SARS-CoV replication is also higher than that of the reported pharmacological therapies such as nelfinavir [12,20]; both drug candidates were reported to have two logs or less inhibition effect on SARS-CoV replication, while ATA showed more than three logs of inhibition effect. The biological activities of ATA have been demonstrated to be quite complicated, including inhibition of protein synthesis, prevention of the attachment of mRNA to ribosomes in cell-free systems, and suppression of enzymes involved in polynucleotide metabolism [21]. How ATA exerts its anti-SARS-CoV activities will require vigorous characterization. Our preliminary result indicated that ATA could inhibit SARS-CoV RNA synthesis (data not shown). Vaccine development could take years to complete and serious adverse reactions have been reported in other coronavirus vaccine studies, i.e., exacerbation of disease in animals received vaccines prior to infection [22]. Certain precautions have been proposed for the development of SARS-CoV vaccines due to potential detrimental effects [23], therefore the search for anti-SARS-CoV drugs must be pursued. Here, we report for the first time that ATA is a potent anti-SARS compound with low toxicity in tissue culture, suggesting that it could have therapeutic value for SARS in patients.

### References

[1] M.A. Marra, S.J.M. Jones, C.R. Astell, R.A. Holt, A. Brooks-Wilson, Y.S.N. Butterfield, J. Kattra, J.K. Asano, S.A. Barber, S.Y. Chan, A. Cloutier, S.M. Coughlin, D. Freeman, N. Girn, O.L. Griffith, S.R. Leach, M. Mayo, H. McDonald, S.B. Montgomery, P.K. Pandoh, A.S. Petrescu, A.G. Robertson, J.E. Schein, A. Siddiqui, D.E. Smallus, J.M. Stott, G.S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T.F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G.A. Tipples, S. Tyler, R. Vorgir, D. Ward, B. Watson, R.C. Brunham, M. Krajden, M. Petric, D.M. Skowrons, C. Upton, R.L. Roper, The genome sequence of the SARS-associated coronavirus, Science 300 (5624) (2003) 1399–1404.

[2] P.A. Rota, M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, J.P. Icenogle, S. Penaranda, B. Bankamp, K. Mahler, M. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J.L. DeRisi, Q. Chen, D. Wang, D.D. Erdman, T.C.T. Peret, C. Burns, T.G. Schein, A. Siddiqui, D.E. Smailus, J.M. Stott, G.S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T.F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G.A. Tipples, S. Tyler, R. Vorgir, D. Ward, B. Watson, R.C. Brunham, M. Krajden, M. Petric, D.M. Skowrons, C. Upton, R.L. Roper, The genome sequence of the SARS-associated coronavirus, Science 300 (5624) (2003) 1399–1404.
Anderson, W.J. Bellini, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, Science 300 (5624) (2003) 1394–1399.

[3] J. Nicholls, X.P. Dong, G. Jiang, M. Peiris, SARS: clinical virology and pathogenesis, Respirology (Suppl.) (2003) S6–S8.

[4] K.V. Holmes, Coronaviruses, in: D.M. Knipe, P.M. Howley (Eds.), Field’s Virology, vol. I, Lippincott, Williams & Wilkins, Philadelphia, 2001, pp. 1187–1203.

[5] J.C. Herholzer, Purification and biophysical properties of human coronavirus 229E, Virology 75 (1) (1976) 255–265.

[6] R.A. Bucknall, A.R. Kalica, R.M. Chanock, Intracellular development and mechanism of hemadsorption of a human coronavirus, OC43, Proc. Soc. Exp. Biol. Med. 139 (3) (1972) 811–817.

[7] L. Van Der Hoek, K. Pyrc, M.F. Jebbink, W. Vermeulen-Oost, R.J. Berkhout, K.C. Wolthers, P.M. Wertheim-Van Dillen, J. Kaandorp, J. Spaargaren, B. Berkhout, Identification of a new human coronavirus, Nat. Med. 10 (4) (2004) 368–373.

[8] R. He, A. Leeson, A. Andonov, Y. Li, N. Bastien, J. Cao, C. Osiowy, F. Dobie, T. Cutts, M. Ballantine, X. Li, Activation of AP-1 signal transduction pathway by SARS coronavirus nucleocapsid protein, Biochem. Biophys. Res. Commun. 311 (4) (2003) 870–876.

[9] R. He, F. Dobie, M. Ballantine, A. Leeson, Y. Li, N. Bastien, T. Cutts, A. Andonov, J. Cao, T. Booth, F.A. Plummer, S. Tyler, L. Baker, X. Li, Analysis of multimerization of SARS-CoV nucleocapsid protein, Biochem. Biophys. Res. Commun. 316 (2) (2004) 476–483.

[10] E.L.C. Tan, E.E. Ooi, C.-Y. Lin, H.C. Tan, A.E. Ling, B. Lim, L.W. Stanton, Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs, Emerg. Infect. Dis. 10 (3) (2004) 581–586.

[11] U. Stroher, A. DiCaro, Y. Li, J.E. Strong, F. Aoki, F. Plummer, S.M. Jones, H. Feldmann, Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha, J. Infect. Dis. 189 (7) (2004) 1164–1167.

[12] J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, H.W. Doerr, Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus, Lancet 361 (9374) (2003) 2045–2046.

[13] S. Talib, J.E. Hearst, Initiation of RNA synthesis in vitro by vesicular stomatitis virus: single internal initiation in the presence of aurintricarboxylic acid and vanadyl ribonucleoside complexes, Nucleic Acids Res. 11 (20) (1983) 7031–7042.

[14] F. Siegelman, D. Apirion, Aurintricarboxylic acid, a preferential inhibitor of initiation of protein synthesis, J. Bacteriol. 105 (3) (1971) 902–907.

[15] M.L. Stewart, A.P. Grollman, M.T. Huang, Aurintricarboxylic acid: inhibitor of initiation of protein synthesis, Proc. Natl. Acad. Sci. USA 68 (1) (1971) 97–101.

[16] O.W. Schmidt, M.K. Cooney, G.E. Kenny, Plaque assay and improved yield of human coronaviruses in a human rhabdomyosarcoma cell line, J. Clin. Microbiol. 9 (6) (1979) 722–728.

[17] J. Balzarini, H. Mitsuya, E. De Clercq, S. Broder, Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus, Biochem. Biophys. Res. Commun. 136 (1) (1986) 64–71.

[18] J.M. Roberts-Lewis, V.R. Marcy, Y. Zhao, J.L. Vaught, R. Siman, M.E. Lewis, Aurintricarboxylic acid protects hippocampal neurons from NMDA- and ischemia-induced toxicity in vivo, J. Neurochem. 61 (1) (1993) 378–381.

[19] M. Cushman, P. Sherman, Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions, Biochem. Biophys. Res. Commun. 185 (1) (1982) 85–90.

[20] N. Yamamoto, R. Yang, Y. Yoshinaka, S. Amari, T. Nakano, J. Cinatl, H. Rabenau, H.W. Doerr, G. Hunsmann, A. Otaka, H. Tamamura, N. Fuji, N. Yamamoto, HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus, Biochem. Biophys. Res. Commun. 318 (3) (2004) 719–725.

[21] W.S. Mellon, Inhibitory action of aurintricarboxylic acid and rifamycin AF/013 at the polynucleotide domain of 1,25-dihydroxyvitamin D3-receptor complexes, Biochem. Pharmacol. 33 (7) (1984) 1047–1057.

[22] D. Cavanagh, Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus, Avian Pathol. 32 (6) (2003) 567–582.

[23] E. Marshall, M. Enserink, Medicine. Caution urged on SARS vaccines, Science 303 (5660) (2004) 944–946.
Update

Biochemical and Biophysical Research Communications
Volume 324, Issue 3, 19 November 2004, Page 1152–1153

DOI: https://doi.org/10.1016/j.bbrc.2004.09.168
Erratum

Erratum to “Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid”
[Biochem. Biophys. Res. Commun. 320 (2004) 1199–1203]

Runtao He\textsuperscript{a,b,*}, Anton Adonova\textsuperscript{a,b}, Maya Traykova-Adonova\textsuperscript{a}, Jingxin Cao\textsuperscript{a,b}, Todd Cutts\textsuperscript{a}, Elsie Grudesky\textsuperscript{a}, Yvon Deschambault\textsuperscript{a}, Jody Berry\textsuperscript{a,b}, Michael Drebota\textsuperscript{a,b}, Xuguang Li\textsuperscript{c}

\textsuperscript{a} National Microbiology Laboratory, Health Canada, 1015 Arlington St., Winnipeg, MB, Canada R3E 3R2
\textsuperscript{b} Department of Medical Microbiology, School of Medicine, University of Manitoba, Winnipeg, MB, Canada R3T 2N2
\textsuperscript{c} Centre for Biologics Research, Biologics and Genetic Therapies Directorate, Health Canada, Tunney’s Pasture, Ottawa, Ont., Canada K1A 0K9

On pages 1201 and 1202 Figs. 2 and 3 were printed with the wrong legends. For the reader’s convenience, both figures appear here with the correct legends.

\textsuperscript{*} Corresponding author. Fax: +1 204 789 2082.
E-mail address: runtao_he@hc-sc.gc.ca (R. He).

DOI of original article: 10.1016/j.bbrc.2004.06.076.
Fig. 3. (A) Vero cells were infected with SARS-CoV and treated with serially diluted concentrations of aurintricarboxylic acid. After 24 h, cells were harvested and subjected to 4–12% SDS–PAGE; protein samples were subsequently transferred to PVDF membrane and probed with a mouse monoclonal antibody against SARS-CoV spike protein and anti-α-actinin antibodies. A rabbit anti-mouse antibody conjugated with horseradish peroxidase was used as the secondary antibody. The blot was subsequently developed with SuperSignal West Femto Western Blot kit. (B) HEK293 cells were transfected with adenovirus X construct expressing EGFP. After 24 h, cells were harvested and subjected to 4–12% SDS–PAGE; protein samples were subsequently transferred to PVDF membrane and probed with mouse monoclonal antibody against EGFP (for HEK293 cell extracts), and anti-α-actinin antibodies. A rabbit anti-mouse antibody conjugated with horseradish peroxidase was used as the secondary antibody. The blot was subsequently developed with SuperSignal West Femto Western Blot kit (Pierce, Rockford, IL).